The EACIP submits its deliberations in the form of a proposal or memorandum to the MOH or the PD-0332991 concentration CCDC. After due consideration, the MOH or the CCDC will disseminate its policy or recommendations as a formal technical guideline. The MOH and CCDC can accept the entirety or just a part of the recommendations made by the EACIP. The main tasks of the EACIP are to advise on the national immunization schedule, to participate in the drafting and review of technical documents, and to provide resource persons in the field supervision and staff training for some specific activities. As noted earlier, China initiated the national EPI in 1978 with the introduction of universal infant vaccination with

BCG, OPV, MV and DTP vaccines. In 2002, China introduced hepatitis B vaccine into the national EPI. In 2007, vaccines against rubella, mumps, meningococcal serotype A and A + C, Japanese encephalitis, and hepatitis A were added to the routine schedule. These changes resulted in an increased number of vaccines requiring appropriate scheduling from both the programme logistics and user perspective. In addition, other improvements were made in the formulation, administration, and dosage of vaccines, e.g., monovalent CX-5461 nmr measles vaccine was replaced by trivalent Measles-Mumps-Rubella (MMR) vaccine, and DTP with whole cell pertussis antigen was replaced by acellular DTaP vaccine. The national EPI also expanded beyond children to include adults, with the potential for vaccines for haemorrhagic fever, leptospirosis, and anthrax for specific high-risk populations. The China EACIP has played an important role in the formulation and modification of the immunization schedule to accommodate vaccines it has recommended previously. In 1986, the EACIP suggested modifications to the immunization schedule based on the scientific data and evidence to ensure

maintenance of high coverage, lower program costs, and fewer vaccination visits by implementing more efficient schedules that combined Methisazone multiple immunizations at the same visit. In 2005, the EACIP recommended changes in the two-dose immunization schedule for measles vaccine from 8 months and 7 years to 8 months and 18 months. At the same time a recommendation was made to increase the dose from 0.2 ml to 0.5 ml to improve vaccine effectiveness. The significant expansion of China’s immunization schedule in 2007 was based on a detailed review of the literature and available evidence. The EACIP identified over 16,623 papers and documents related to vaccines against measles, mumps, rubella, meningococcal meningitis, Japanese encephalitis, and hepatitis A. Using a systematic review process and meta-analysis, 1550 papers were selected according to pre-defined criteria, and 202 papers were analyzed in detail (Table 1).